Chronic LeukemiasTopic Compilations Chronic Leukemias Thursday, January 6, 2000 A collection of features and news articles published in ASH Clinical News related to chronic leukemias. Liso-Cel Shows Promising Safety and Efficacy in Relapsed/Refractory CLL/SLL In patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), treatment with lisocabtagene maraleucel (liso-cel) was associated with deep, rapid responses... How Long Is the Indolent Preclinical Phase of High-Risk CLL? The indolent preclinical phase of chronic lymphocytic leukemia (CLL) may be longer than previously thought, with some high-risk subtypes of CLL occurring as many... Frontline, Time-Limited Acalabrutinib, Venetoclax, and Obinutuzumab Active in Treatment-Naïve CLL A frontline, time-limited triplet therapy comprising acalabrutinib, venetoclax, and obinutuzumab showed favorable activity and tolerability in patients with chronic lymphocytic leukemia (CLL), according to... Disease Detectives: CLL in Asia Researchers continue to investigate why rates of chronic lymphocytic leukemia remain lower in Asian populations. In the United States, chronic lymphocytic leukemia (CLL) accounts for... Does MRD Predict PFS in Patients With CLL on Indefinite Ibrutinib-Based Therapy? According to research published in Blood, measurable residual disease (MRD) was not associated with improved progression-free survival (PFS) in patients with chronic lymphocytic leukemia... Asciminib Superior to Bosutinib in Chronic-Phase CML Asciminib was more effective than bosutinib at improving the rate of a major molecular response in patients with chronic myeloid leukemia in chronic phase... Ibrutinib Plus Venetoclax Shows Promise in Treatment-Naïve CLL First-line combination therapy with ibrutinib and venetoclax was associated with higher rates of undetectable measurable residual disease (MRD), remission, and three-year progression-free survival (PFS)... Functional, Nutritional, and Social Status Predict Survival Outcomes in Older Patients With CLL Geriatric domains of functional status, social activity, and nutritional status were associated with overall survival (OS) and progression-free survival (PFS) in older adults with... Head-to-Head Trial Confirms Acalabrutinib’s Noninferiority to Ibrutinib in CLL At EHA2021 Virtual, researchers presented results from the first head-to-head trial of Bruton tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia (CLL), finding that... Evaluating Maintenance Therapy After Fixed-Duration Obinutuzumab Plus Venetoclax in CLL For patients with chronic lymphocytic leukemia (CLL) who are considered unfit for FCR chemotherapy (fludarabine, cyclophosphamide, rituximab), a fixed-duration regimen of venetoclax plus obinutuzumab...